Triple Therapy Lessens Severe COPD Exacerbations & All-Cause Mortality
Among patients with COPD, the triple therapy of single-inhaler fluticasone furoate (FF)/ umeclidinium ( UMEC)/ vilanterol (VI) significantly reduced severe exacerbation rates and all-cause mortality (ACM) risk versus the dual...
Read More